EGFR and non-small cell lung carcinoma: Preclinical findings showed that the therapy with EGFR-TKI increases HER3 expression, thus improving the anticancer activity of patritumab deruxtecan [150] and providing a rationale for an ongoing study which is evaluating patritumab deruxtecan plus osimertinib in patients with advanced EGFR-mutated NSCLC (NCT04676477).